Pasqualetti Francesco, Lombardi Giuseppe, Gadducci Giovanni, Giannini Noemi, Montemurro Nicola, Feletti Alberto, Zeppieri Marco, Somma Teresa, Caffo Maria, Bertolotti Chiara, Ius Tamara
Division of Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, 56100 Pisa, Italy.
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
J Pers Med. 2024 Aug 25;14(9):899. doi: 10.3390/jpm14090899.
Gliomas of the brainstem represent a small percentage of central nervous system gliomas in adults. Due to the proximity of the tumor to critical structures, radical surgery is highly challenging and limited to selected cases. In addition, postoperative treatments, which become exclusive to non-operable patients, do not guarantee satisfactory disease control, making the progression of the disease inevitable. Currently, there is a lack of therapeutic options to control tumor growth after the diagnosis of recurrence. The rarity of these tumors, their distinct behavioral characteristics, and the limited availability of tumor tissue necessary for the development of prognostic and predictive biomarkers contribute to the absence of a standardized approach for treating recurrent brainstem gliomas. A salvage radiotherapy (RT) retreatment could represent a promising approach for recurrent brainstem gliomas. However, to date, it has been mainly evaluated in pediatric cases, with few experiences available to assess the most appropriate RT dose, safety, and clinical responses in adult patients. This comprehensive review aims to identify instances of adult patients with recurrent brainstem gliomas subjected to a secondary course of RT, with a specific focus on the analysis of treatment-related toxicity and outcomes. Through this investigation, we endeavor to contribute valuable insights into the viability and efficacy of salvage RT retreatment in managing recurrent brainstem gliomas in the adult population.
脑干胶质瘤在成人中枢神经系统胶质瘤中占比很小。由于肿瘤靠近关键结构,根治性手术极具挑战性,仅适用于特定病例。此外,术后治疗是无法手术患者的唯一选择,但并不能保证令人满意的疾病控制效果,疾病进展难以避免。目前,复发诊断后缺乏控制肿瘤生长的治疗选择。这些肿瘤的罕见性、独特的行为特征以及开发预后和预测生物标志物所需肿瘤组织的有限可得性,导致缺乏治疗复发性脑干胶质瘤的标准化方法。挽救性放疗(RT)再治疗可能是复发性脑干胶质瘤的一种有前景的方法。然而,迄今为止,主要在儿科病例中进行了评估,几乎没有经验可用于评估成人患者最合适的放疗剂量、安全性和临床反应。这篇综述旨在确定接受二次放疗的复发性脑干胶质瘤成年患者的病例,特别关注与治疗相关的毒性和结果分析。通过这项研究,我们努力为挽救性放疗再治疗在管理成年复发性脑干胶质瘤中的可行性和疗效提供有价值的见解。